Skip to main content
. 2023 Jul 28;12(7):1079–1089. doi: 10.21037/tau-22-684

Table 1. Demographics of male patients with pancreatic cancer from chart review and serum sample cohorts.

Covariate Level Chart review cohort (cohort A) (n=35) Serum sample cohort (cohort B) (n=89)
Age at diagnosis (years) Median (range) 61.9 (22.7–87.5) 66.0 (44.0–87.0)
Race African American 0 (0.0) 3 (3.4)
White 35 (100.0) 85 (95.5)
Unknown 0 (0.0) 1 (1.1)
BMI at diagnosis (kg/m2) Median (range) 31.3 (13.7–59.7) 27.8 (17.2–52.2)
Obese (BMI >30 kg/m2) Yes 20 (57.1) 34 (38.2)
No 15 (42.9) 55 (61.8)
Diabetes Yes 16 (45.7) 38 (42.7)
No 19 (54.3) 51 (57.3)
Heart disease Yes 18 (51.4) 63 (70.8)
No 17 (48.6) 26 (29.2)
Hypo/hyperthyroidism Yes 6 (17.1) 10 (11.2)
No 29 (82.9) 79 (88.8)
Obstructive sleep apnea Yes 4 (11.4) 12 (13.5)
No 31 (88.6) 77 (86.5)
HIV/AIDS Yes 0 (0.0) 0 (0.0)
No 35 (100.0) 89 (100.0)
Chronic kidney disease Yes 2 (5.7) 3 (3.4)
No 33 (94.3) 86 (96.6)
Sarcoidosis Yes 0 (0.0) 0 (0.0)
No 35 (100.0) 89 (100.0)
Corticosteroid use Yes 2 (5.7) 5 (5.6)
No 33 (94.3) 84 (94.4)
Opioid use Yes 5 (14.3) 25 (28.1)
No 30 (85.7) 64 (71.9)
Pre-existing autoimmune disease Yes 1 (2.9) 3 (3.4)
No 34 (97.1) 86 (96.6)
Previous cancer diagnosis Yes 7 (20.0) 22 (24.7)
No 28 (80.0) 67 (75.3)
Clinical stage I 8 (22.9) 17 (19.1)
II 7 (20.0) 38 (42.7)
III 2 (5.7) 13 (14.6)
IV 17 (48.6) 21 (23.6)
Not staged 1 (2.9) 0 (0.0)
Histology Adenocarcinoma 18 (51.4) 89 (100.0)
Neuroendocrine tumor 17 (48.6) 0 (0.0)
Testosterone level (ng/dL) Median (range) 365 (5–1,497) 301 (123–2,378)
Low testosterone (<300 ng/dL) Yes 20 (57.1) 44 (49.4)
No 15 (42.9) 45 (50.6)
Prior testosterone assessment Yes 2 (2.2)
No 87 (97.8)
Symptoms of low testosterone Yes 62 (69.7)
No 27 (30.3)

Except where otherwise noted, data are presented as n (%). BMI, body mass index; HIV/AIDS, human immunodeficiency virus or acquired immunodeficiency syndrome.